Abstract
The 2022 global outbreak of clade IIb mpox represented a turning point in public health’s handling of poxviruses. The primary vaccine available for prevention of mpox is modified vaccinia Ankara from Bavarian-Nordic (MVA-BN). We previously reported a nondurable and low avidity antibody response against mpox elicited by MVA-BN. In this study, we expanded upon this knowledge by employing a microneutralization assay to measure monkeypox virus (MPXV) neutralizing titers and a multiplexed immunoassay to assess IgG titers and avidity against eight MPXV antigens and two vaccinia antigens. Through a machine learning analysis, we uncovered that MVA-BN vaccinees without prior smallpox vaccination largely return to a baseline seroprofile within a year of immunization. Notably, we identified a discrete population within this group that mounted a robust neutralizing antibody response associated with a longer dosing interval during the MVA-BN primary series. Furthermore, we found that boosting with a third dose of MVA-BN increases IgG avidity against certain MPXV antigens, as part of a booster-specific seroprofile. These findings provide critical insights into optimizing immune responses through MVA-BN boosters, presenting a promising approach to addressing the limited MPXV-specific immunity observed following the primary series.
Competing Interest Statement
M.J.M. reported potential competing interests: laboratory research and clinical trials contracts for vaccines or MAB with Lilly, Pfizer, and Sanofi; research grant funding from USG/HHS/NIH for vaccine and MAB clinical trials; personal fees for Scientific Advisory Board service from Hillevax, Merck, Meissa Vaccines, Sanofi, Pfizer, and GSK.
Clinical Protocols
https://clinicaltrials.gov/study/NCT05654883
Funding Statement
Financial support was provided by the Blavatnik Family Foundation, the National Institutes of Health (NIH) grants no. AI148574 and 75N93021C00014 (to M.J.M.) and T32AI100853 (supporting A.L.O.), the NYC Department of Health and Mental Hygiene, and NYU Grossman School of Medicine institutional support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NYC Observational Study of Mpox Immunity cohort has been registered with ClinicalTrials.gov (NCT05654883) and received approval from the New York University Institutional Review Board (protocol 22-01338). Additional samples obtained from the NYU Langone Vaccine Center Biorepository were under NYU Institutional Review Board protocol 18-02035. Samples from Crandell et al. were obtained under the following authorities: Yale Human Research Protection Program Institutional Review Board (protocol ID 2000033415), the Research Ethics Committee of the Hospital Universitario Clementino Fraga Filho Universidade Federal do Rio de Janeiro (protocol number CAAE 62281722.5.0000.5257), and the Portuguese General Directorate of Health, through the technical orientation number 004/2022 on May 31, 2022. Written informed consent was obtained from all participants prior to participation in each study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors and will be fully available following publication.
